Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.

Duan XY, Liu SY, Yin DG

Medicine1 Jul 2021Cited by 23 (Europe PMC)

PMID34397684PMCIDPMC8322563DOI10.1097/md.0000000000026431PepBankPUB-34397684

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, subcutaneous semaglutide lowered MACE versus lixisenatide in a network meta-analysis.
In plain wordsIn adults with type 2 diabetes, injected semaglutide lowered serious heart and vessel events compared with lixisenatide in a pooled network analysis.
Peptide
Semaglutide
Outcome
DecreaseMACE versus lixisenatide
Study
n: not reported in source
Comparator
Lixisenatide
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
Sotagliflozin (HR 0.76, 95% CI 0.61-0.94), subcutaneous semaglutide, and albiglutide lowered MACE versus lixisenatide among others.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed and Embase for relevant cardiovascular or renal outcome trials (CVOTs).
Summary · context
Bayesian network meta-analysis was conducted to produce pooled hazard ratio (HR) and 95% confidence interval (CI).
Report a problemFND-3439768401
02HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, oral semaglutide lowered cardiovascular death versus dapagliflozin in a network meta-analysis.
In plain wordsIn adults with type 2 diabetes, oral semaglutide lowered deaths from heart and vessel causes compared with dapagliflozin in a pooled network analysis.
Peptide
Semaglutide
Outcome
DecreaseCardiovascular death versus dapagliflozin
Study
n: not reported in source
Comparator
Dapagliflozin
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · oralAs given in this study (human).
Source sentences
Summary
Empagliflozin and oral semaglutide lowered CVD versus dapagliflozin among others.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed and Embase for relevant cardiovascular or renal outcome trials (CVOTs).
Summary · context
Bayesian network meta-analysis was conducted to produce pooled hazard ratio (HR) and 95% confidence interval (CI).
Report a problemFND-3439768402
03HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, subcutaneous semaglutide lowered stroke versus empagliflozin in a network meta-analysis.
In plain wordsIn adults with type 2 diabetes, injected semaglutide lowered stroke compared with empagliflozin in a pooled network analysis.
Peptide
Semaglutide
Outcome
DecreaseStroke versus empagliflozin
Study
n: not reported in source
Comparator
Empagliflozin
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
Sotagliflozin (HR 0.56, 95% CI 0.37-0.85) and subcutaneous semaglutide lowered stroke versus empagliflozin among others.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed and Embase for relevant cardiovascular or renal outcome trials (CVOTs).
Summary · context
Bayesian network meta-analysis was conducted to produce pooled hazard ratio (HR) and 95% confidence interval (CI).
Report a problemFND-3439768403
04HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, oral semaglutide lowered all-cause death versus subcutaneous semaglutide in a network meta-analysis.
In plain wordsIn adults with type 2 diabetes, oral semaglutide lowered deaths from any cause compared with injected semaglutide in a pooled network analysis.
Peptide
Semaglutide
Outcome
DecreaseAll-cause death, oral versus subcutaneous semaglutide
Study
n: not reported in source
Comparator
Subcutaneous semaglutide
Outcome group
Mortality · Whole body
Studied dose
Dose not stated · oralAs given in this study (human).
Source sentences
Summary
Oral semaglutide and empagliflozin lowered ACD versus subcutaneous semaglutide among others.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed and Embase for relevant cardiovascular or renal outcome trials (CVOTs).
Summary · context
Bayesian network meta-analysis was conducted to produce pooled hazard ratio (HR) and 95% confidence interval (CI).
Report a problemFND-3439768404
05HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, subcutaneous semaglutide ranked second, after sotagliflozin, for lowering MACE by SUCRA.
In plain wordsIn adults with type 2 diabetes, injected semaglutide ranked second among agents for lowering serious heart and vessel events.
Peptide
Semaglutide
Outcome
DecreaseSUCRA ranking for lowering MACE
Study
n: not reported in source
Comparator
Other agents in the network
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
sotagliflozin, subcutaneous semaglutide, and albiglutide in lowering MACE
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed and Embase for relevant cardiovascular or renal outcome trials (CVOTs).
Summary · context
Bayesian network meta-analysis was conducted to produce pooled hazard ratio (HR) and 95% confidence interval (CI).
Report a problemFND-3439768405
06HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, subcutaneous semaglutide ranked second, after sotagliflozin, for lowering stroke by SUCRA.
In plain wordsIn adults with type 2 diabetes, injected semaglutide ranked second among agents for lowering stroke.
Peptide
Semaglutide
Outcome
DecreaseSUCRA ranking for lowering stroke
Study
n: not reported in source
Comparator
Other agents in the network
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
sotagliflozin and subcutaneous semaglutide in lowering stroke
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed and Embase for relevant cardiovascular or renal outcome trials (CVOTs).
Summary · context
Bayesian network meta-analysis was conducted to produce pooled hazard ratio (HR) and 95% confidence interval (CI).
Report a problemFND-3439768406
07HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, oral semaglutide ranked second, after empagliflozin, for lowering cardiovascular death by SUCRA.
In plain wordsIn adults with type 2 diabetes, oral semaglutide ranked second among agents for lowering deaths from heart and vessel causes.
Peptide
Semaglutide
Outcome
DecreaseSUCRA ranking for lowering cardiovascular death
Study
n: not reported in source
Comparator
Other agents in the network
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · oralAs given in this study (human).
Source sentences
Summary
empagliflozin and oral semaglutide in lowering CVD
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed and Embase for relevant cardiovascular or renal outcome trials (CVOTs).
Summary · context
Bayesian network meta-analysis was conducted to produce pooled hazard ratio (HR) and 95% confidence interval (CI).
Report a problemFND-3439768407
08HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, oral semaglutide ranked first, before empagliflozin, for lowering all-cause death by SUCRA.
In plain wordsIn adults with type 2 diabetes, oral semaglutide ranked first among agents for lowering deaths from any cause.
Peptide
Semaglutide
Outcome
DecreaseSUCRA ranking for lowering all-cause death
Study
n: not reported in source
Comparator
Other agents in the network
Outcome group
Mortality · Whole body
Studied dose
Dose not stated · oralAs given in this study (human).
Source sentences
Summary
oral semaglutide and empagliflozin in lowering ACD
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed and Embase for relevant cardiovascular or renal outcome trials (CVOTs).
Summary · context
Bayesian network meta-analysis was conducted to produce pooled hazard ratio (HR) and 95% confidence interval (CI).
Report a problemFND-3439768408
09HumanSystematic reviewEfficacy outcome
In adults with type 2 diabetes, a network meta-analysis found hospitalization for heart failure was lower with sotagliflozin (HR 0.59, 95% CI 0.40-0.89), canagliflozin and empagliflozin than with subcutaneous semaglutide.
In plain wordsIn adults with type 2 diabetes, a pooled analysis linked injected semaglutide to more heart-failure hospital stays than sotagliflozin, canagliflozin or empagliflozin.
Peptide
Semaglutide
Outcome
IncreaseHospitalization for heart failure versus SGLT2 inhibitors (subcutaneous semaglutide as comparator)
Study
n: not reported in source
Comparator
Sotagliflozin, canagliflozin and empagliflozin
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · subcutaneousAs given in this study (human).
Source sentences
Summary
Sotagliflozin (HR 0.59, 95% CI 0.40-0.89), canagliflozin, and empagliflozin lowered HHF versus subcutaneous semaglutide among others.
Report a problemFND-3439768409

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.